Login to Your Account

Other News To Note

Thursday, July 21, 2011
Regulus Therapeutics Inc., of La Jolla, Calif., identified a third microRNA target in its alliance with GlaxoSmithKline plc (GSK), of London, triggering a preclinical milestone payment from GSK. Under the alliance, Regulus has the potential to earn more than $600 million in payments, including license and milestone payments and tiered royalties up to double digits on worldwide sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription